Vanda Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)
FDA-2022-N-2390-0669Notice
Comments
0
Awaiting comments
Deadline
Closed on Jul 7, 2026
Closed Jul 7, 2026
Net supportiSupport minus oppose · campaigns included
—
Document
Details
The document's own metadata, straight from the source system.
- Title
- Vanda Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)
- Posted
- Jun 3, 2026
- Comment period
- Jun 3, 2026 – Jul 7, 2026
- FR Doc
- 2026-11046
- Topics
Analysis
Overview
No comments yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
No comments match.